Prediction: Grail Stock Will Skyrocket to $100 in 1 Year
The cancer test maker still has a bright future.
Overview
Grail (NASDAQ: GRAL), which was spun off from Illumina (NASDAQ: ILMN) in 2024, set a record high of $116.06 on Jan. 22. At the time, its Galleri blood test -- which aims to detect signals from dozens of cancers before any symptoms appear -- seemed like a game changer.
But today, Grail's stock trades at about $69. Most of that decline occurred after its largest NHS England trial for Galleri failed to meet its primary endpoint in February. Let's see why that setback doesn't spell doom for Grail -- and why it could still soar to $100 over the next year.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.